纽约纪念斯隆-凯特琳癌症中心的研究主持人Helena A.Yu医学博士说,在这项2期试验中,patritumab deruxtecan为那些在接受EGFR酪氨酸激酶抑制剂(TKI)治疗和基于铂的化疗后病情进展的患者提供了“有临床意义和持久的疗效”。 该试验名为HERTHENA-Lung01(ClinicalTrials.gov标识符:NCT04619004),包括225名EGFR突变型NSCLC患...
Patritumab deruxtecan是将抗HER3抗体与拓扑异构酶抑制剂通过四肽连接子连接而成HER3靶向抗体偶联药物。ESMO 2020上公布了最新patritumab deruxtecan在治疗转移性或不可切除的非小细胞肺癌(NSCLCL)患者的I期临床数据。试验结果表明,携带EGFR突变,并已接受过多种酪氨酸激酶抑制剂(TKI)的治疗的难治性患者Patritumab d...
如果获得批准,patritumab deruxtecan将成为这些患者的第一个HER3导向的DXd抗体药物缀合物。 该申请得到了随机、开放标签、关键的2期HERTHENA-Lung01试验(ClinicalTrials.gov标识符:NCT04619004)数据的支持,该试验评估了在至少1种EGFR酪氨酸...
如果获得批准,patritumab deruxtecan将成为这些患者的第一个HER3导向的DXd抗体药物缀合物 。 该申请得到了随机、开放标签、关键的2期HERTHENA-Lung01试验(ClinicalTrials.gov标识符:NCT04619004)数据的支持,该试验评估了在至少1种EGFR酪氨酸激酶抑制剂(TKI)和1种铂类化疗后疾病进展的225名患有EGFR突变的局部晚期或...
The safety profile of patritumab deruxtecan observed in HERTHENA-Lung01 was consistent with previous phase 1 clinical trials in NSCLC with a treatment discontinuation rate of 7.1% due to treatment-emergent adverse events (TEAEs). Grade 3 or higher TEAEs ...
Patritumab deruxtecan (also known as U3 1402) is an antibody drug conjugate (ADC), being developed by Daiichi Sankyo Company, for the treatment of solid
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials with no new safety signals identified. The majority of interstitial lung disease (ILD) events were low grade (grade 1 and 2). There were two grade ...
Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SR...
-assessed ORR; safety, tolerability and preliminary efficacy; and characterization of the pharmacokinetics of patritumab deruxtecan. The study is currently enrolling patients at multiple sites in the U.S., Europe, Japan and other countries in Asia...
“We look forward to engaging and collaborating with the deep expertise and cutting-edge oncology research capabilities of Gustave Roussy, the premier European Cancer Center, to further advance clinical development of DS-1062 and patritumab deruxtecan,” said Antoine Yver, MD, MSc, AIHP, ACCA Pa...